Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Exp Parasitol ; 246: 108475, 2023 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-36707015

RESUMO

Malaria remains as a global life-threatening disorder due to the emergence of resistance against standard antimalarials. Consequently, there is a serious need to better understand the biology of the malaria parasite in order to determine appropriate targets for new interventions. Calcyclin binding protein (CacyBP) is a multi-functional and multi-ligand protein that is not well characterized in malaria disease. In this study, we have cloned CacyBP from rodent species Plasmodium yoelii nigeriensis and purified the recombinant protein to carry out its detailed molecular, biophysical and immunological characterization. Molecular characterization indicates that PyCacyBP is a ∼27 kDa protein in parasite lysate and exists in monomer and dimer forms. Bioinformatic analysis of CacyBP showed significant sequence and structural similarities between rodent and human malaria parasites. CacyBP is expressed in all blood stages of P. yoelii nigeriensis parasite. In silico studies proposed the immunogenic potential of CacyBP. The rPyCacyBP immunized mice exhibited elevated levels of IgG1, IgG2a, IgG2b and IgG3 in their serum. Notably, cellular immune response in splenocytes from immunized mice showed increased expression of pro-inflammatory cytokines such as IL-12, IFN-γ and TNF-α. This CacyBP exhibited pro-inflammatory immune response in rodent host. These finding revealed that CacyBP may have the potential to boost the host immunity for protection against malaria infection. The present study provides basis for further exploration of the biological function of CacyBP in malaria parasite.


Assuntos
Antimaláricos , Malária , Parasitos , Plasmodium yoelii , Humanos , Animais , Camundongos , Parasitos/metabolismo , Proteína A6 Ligante de Cálcio S100 , Malária/tratamento farmacológico , Antimaláricos/uso terapêutico , Imunidade Celular , Plasmodium yoelii/genética , Proteínas de Ligação ao Cálcio/metabolismo , Proteínas de Ligação ao Cálcio/uso terapêutico
2.
Parasitology ; 146(12): 1571-1577, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31244453

RESUMO

Cerebral malaria (CM) is the severe neurological complication causing acute non-traumatic encephalopathy in tropical countries. The mechanisms underlying the fatal cerebral complications are still not fully understood. Glutamate, a major excitatory neurotransmitter in the central nervous system of the mammalian brain, plays a key role in the development of neuronal cells, motor function, synaptic plasticity, learning and memory processes under normal physiological conditions. The subtypes of ionotropic glutamate receptor are N-methyl-D-aspartate receptors (NMDARs) which are involved in cellular mechanisms of learning and memory, synaptic plasticity and also mediate excitotoxic neuronal injury. In the present study, we found that glutamate level in synaptosomes, as well as expression of NMDAR, was elevated during the extreme condition of CM in C57BL6 mice. Arteether at 50 mg kg-1 × 1, 25 mg kg-1 × 2, days decreased the NMDAR expression and increased the overall survival of the experimental CM mice.


Assuntos
Antimaláricos/farmacologia , Artemisininas/farmacologia , Expressão Gênica/efeitos dos fármacos , Malária Cerebral/tratamento farmacológico , Receptores de N-Metil-D-Aspartato/genética , Animais , Feminino , Longevidade/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL
3.
Apoptosis ; 21(9): 955-64, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27357656

RESUMO

Recent studies pioneer the existence of a novel programmed cell death pathway in malaria parasite plasmodium and suggest that it could be helpful in developing new targeted anti-malarial therapies. Considering this fact, we evaluated the underlying action mechanism of this pathway in mefloquine (MQ) treated parasite. Since cysteine proteases play a key role in apoptosis hence we performed preliminary computational simulations to determine binding affinity of MQ with metacaspase protein model. Binding pocket identified using computational studies, was docked with MQ to identify it's potential to bind with the predicted protein model. We further determined apoptotic markers such as mitochondrial dysregulation, activation of cysteine proteases and in situ DNA fragmentation in MQ treated/untreated parasites by cell based assay. Our results showed low mitochondrial membrane potential, enhanced activity of cysteine protease and increased number of fragmented DNA in treated parasites compared to untreated ones. We next tested the involvement of oxidative stress in MQ mediated cell death and found significant increase in reactive oxygen species generation after 24 h of treatment. Therefore we conclude that apart from hemozoin inhibition, MQ is competent to induce apoptosis in plasmodium by activating metacaspase and ROS production.


Assuntos
Apoptose/efeitos dos fármacos , Malária/parasitologia , Mefloquina/farmacologia , Plasmodium/citologia , Plasmodium/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Fragmentação do DNA/efeitos dos fármacos , Humanos , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Plasmodium/metabolismo
4.
Parasitology ; 143(12): 1557-68, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27440106

RESUMO

Cerebral malaria (CM) shows lethality rate of 15-25% despite effective antimalarial chemotherapy. The effective adjunct treatment to counteract the CM pathogenesis is urgently required. In murine CM model, most interventions studied till date are administered before the onset of CM symptoms, which belittle its translational value to human. We studied intramuscular arteether-vitamin D (ART-VD) combination treatment for CM outcome improvement after the onset of neurological symptoms. The intramuscular dose of 50 µg kg-1 VD for 3 days combined with a loading dose of 25 mg kg-1 α/ß arteether followed by 12·5 mg kg-1 dose for two consecutive days led to significant improvement in survival (73% in combination group vs 29 and 0% in arteether and VD monotherapy, respectively) and clinical recovery. The treatment in all the groups partially restored the blood-brain barrier integrity and reduced the level of serum proinflammatory cytokines tumour necrosis factor-α and interferon-γ. The brain transcripts of inflammatory chemokines viz. CXCL10, CXCL9, CCL4 and CCL5 and T cell migration in the brain microvasculature were significantly diminished in all the treatment groups. ART-VD treatment significantly reduced intercellular cell adhesion molecule-1 expression. Taken together, our findings show that coordinated actions of ART-VD improve the outcome of experimental CM.


Assuntos
Antimaláricos/administração & dosagem , Artemisininas/administração & dosagem , Malária Cerebral/tratamento farmacológico , Vitamina D/administração & dosagem , Animais , Encéfalo/patologia , Citocinas/biossíntese , Modelos Animais de Doenças , Quimioterapia Combinada/métodos , Perfilação da Expressão Gênica , Injeções Intramusculares , Camundongos , Análise de Sobrevida , Resultado do Tratamento
5.
Parasitology ; 143(11): 1421-32, 2016 09.
Artigo em Inglês | MEDLINE | ID: mdl-27230403

RESUMO

Aiming to develop new artemisinin-based combination therapy (ACT) for malaria, antimalarial effect of a new series of pyrrolidine-acridine hybrid in combination with artemisinin derivatives was investigated. Synthesis, antimalarial and cytotoxic evaluation of a series of hybrid of 2-(3-(substitutedbenzyl)pyrrolidin-1-yl)alkanamines and acridine were performed and mode of action of the lead compound was investigated. In vivo pharmacodynamic properties (parasite clearance time, parasite reduction ratio, dose and regimen determination) against multidrug resistant (MDR) rodent malaria parasite and toxicological parameters (median lethal dose, liver function test, kidney function test) were also investigated. 6-Chloro-N-(4-(3-(3,4-dimethoxybenzyl)pyrrolidin-1-yl)butyl)-2-methoxyacridin-9-amine (15c) has shown a dose dependent haem bio-mineralization inhibition and was found to be the most effective and safe compound against MDR malaria parasite in Swiss mice model. It displayed best antimalarial potential with artemether (AM) in vitro as well as in vivo. The combination also showed favourable pharmacodynamic properties and therapeutic response in mice with established MDR malaria infection and all mice were cured at the determined doses. The combination did not show toxicity at the doses administered to the Swiss mice. Taken together, our findings suggest that compound 15c is a potential partner with AM for the ACT and could be explored for further development.


Assuntos
Antimaláricos/farmacologia , Artemisininas/farmacologia , Malária Falciparum/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Pirrolidinas/farmacologia , Acridinas/farmacocinética , Acridinas/uso terapêutico , Acridinas/toxicidade , Animais , Antimaláricos/efeitos adversos , Antimaláricos/uso terapêutico , Antimaláricos/toxicidade , Artemeter , Artemisininas/administração & dosagem , Artemisininas/farmacocinética , Artemisininas/uso terapêutico , Artemisininas/toxicidade , Resistência a Múltiplos Medicamentos , Quimioterapia Combinada , Dose Letal Mediana , Malária Falciparum/parasitologia , Camundongos , Parasitemia/tratamento farmacológico , Pirrolidinas/farmacocinética , Pirrolidinas/uso terapêutico , Pirrolidinas/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...